

October 26, 2021

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Mothers Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8045  
URL: <https://solasia.co.jp/en/>

## **Solasia Announces Change in Commercial Partner for SP-02 in Japan**

Tokyo, Japan, October 26<sup>th</sup>, 2021 – Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), today announced the conclusion of a license agreement with Nippon Kayaku Co., Ltd. (TSE: 4272) for marketing rights to new drug candidate darinaparsin (SP-02), upon termination of the license agreement with Meiji Seika Pharma Co., Ltd. for exclusive development and marketing rights to SP-02 in Japan.

For details regarding the license agreement with Nippon Kayaku, please see the separate press release disclosed today.

SP-02 is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma. Solasia filed a new drug application with the Ministry of Health, Labour and Welfare in June 2021 and expects to launch after obtaining approval from the agency in 2022. Due to the change in commercial partner, SP-02 will be marketed and sold by Nippon Kayaku.

With the conclusion of the license agreement with Nippon Kayaku, Solasia will receive up to 7.7 billion yen in upfront and milestone payments in accordance with its development and sales milestones for SP-02. Further, Solasia will earn revenue from its supply of SP-02 to Nippon Kayaku. The upfront payment received from Nippon Kayaku will be recorded in the financial results for the fiscal year ending December 2021, but it is expected to have a minimal impact on Solasia’s earnings forecast for the fiscal year announced February 10, 2021. Hence, Solasia made no change to the earnings forecast.

### Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company’s actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. We do not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.